Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. The company was incorporated in 1999 and is based in Lund, Sweden.
Frequently asked questions
What sector does Spago Nanomedical AB (SPAGO) operate in?
Spago Nanomedical AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Spago Nanomedical AB (SPAGO) current stock price?
As of the latest data, Spago Nanomedical AB stock price is SEK 0.12, with a previous close of SEK 0.11. Spago Nanomedical AB gained SEK 0.00 in the last trading session, representing a 1.32% increase.
What is Spago Nanomedical AB (SPAGO) current market capitalization?
Spago Nanomedical AB market cap is approximately 92.21 million.
What is Spago Nanomedical AB (SPAGO) Earnings Per Share (EPS)?
The trailing EPS is -SEK 0.06, and the forward EPS is -SEK 0.07.
What is Spago Nanomedical AB (SPAGO) EBITDA?
Spago Nanomedical AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.90 million.
Does Spago Nanomedical AB (SPAGO) pay dividends?
No. Spago Nanomedical AB does not pay a dividend.
What is Spago Nanomedical AB (SPAGO) beta (volatility) score?
Spago Nanomedical AB has a beta of 1.298, suggesting it is more volatile than the market.
